Adaptive Biotechnologies and Genentech will conclude their nearly six-and-a-half-year collaboration to develop personalized cancer cell therapies. The partnership used Adaptive’s T cell receptor screening platform to identify TCRs targeting neoantigens, with Genentech advancing clinical development. Adaptive will recognize $33.7 million in remaining non-cash revenues from the deal. The separation frees Adaptive from exclusivity in oncology cell therapies, opening new collaboration opportunities.